Introduction
Chemotherapy-induced nausea and vomiting (CINV) causes patients considerable emotional and physical distress, greatly diminishing quality of life (1). Japan has developed clinical practice guidelines that support and aid the implementation of evidence-based practices (2), covering usage of aprepitant, a selective neurokinin 1 receptor antagonist, as well as first-generation granisetron and second-generation palonosetron [5-hydroxytryptamine type 3 (5-HT3) receptor antagonists]. Previous studies have made significant progress in the development of supportive therapies for patients receiving cisplatin and doxorubicin + cyclophosphamide; this includes anti-emetic drugs for highly emetogenic chemotherapy (HEC) regimens (3,4). Anti-emetic treatment recommendations for patients receiving HEC (5,6) and moderately emetogenic chemotherapy (7–9) for the treatment of solid tumors are now well established, and evidence suggests that palonosetron is fairly effective (10).
CINV comprises two of the most unpleasant chemotherapy-associated side effects for patients with cancer, and numerous studies (3–9) have been conducted since 2012 to assess the effectiveness of a growing list of anticancer drug options that are able to reduce CINV. However, balanced against the effectiveness of the treatment as a supportive drug, the cost burden remains a major concern.
Findings from the TRIPLE TEST clinical trial (11), published in 2013 revealed that palonosetron markedly improved the complete recovery (CR) rate during the delayed phase compared with other drug options. The TRIPLE TEST was originally used to assess the advanced emetic risk of cisplatin regimens, but acute and delayed phases overlap in remission induction therapy and other daily continuous administration regimens. This study demonstrated that palonosetron was remarkably effective for controlling acute vomiting.
Patients with hematological tumors (as opposed to solid tumors) are generally younger and have greater risk of CINV due to highly emetogenic treatments and other psychological factors. Unfortunately, there are currently no collective international guidelines for combating CINV in these patients.
The current study is a retrospective comparative analysis of the anti-emetic effects of granisetron and palonosetron when used during remission induction therapy and consolidation therapy of patients with acute myeloid leukemia.
Discussion
The efficacy of palonosetron may be attributed to its long plasma elimination half-life and high receptor binding affinity (12) compared with other 5-HT3 receptor antagonists. The superior anti-emetic efficacy of palonosetron compared with other 5-HT3 receptor antagonists may also be attributed to allosteric interactions and a positive cooperative effect of palonosetron, prolonged structural changes of the receptor and internalization (13–15), in addition to other factors.
Several investigators reported that palonosetron provides more effective CINV control through the entire chemotherapy process (including the delayed phase) than any other 5-HT3 receptor to date (16,17). The present results similarly observed that palonosetron is effective for controlling acute- and delayed-phase nausea through the entire treatment period.
Compared with the short half-life of granisetron, 3.14±1.20 h (17), palonosetron is eliminated from the body very slowly and has a markedly longer half-life of 41.6±13.1 h (18). Hothersall et al (19) reported that palonosetron acts as a 5-HT3 receptor over a prolonged period or even as an irreversible antagonist for at least 4 days. Allosteric receptor-receptor interactions may play a significant role in this phenomenon (19). The key objective of the present study was to identify a continuous daily regimen of anti-emetic drugs that may be used during remission induction therapy. The results revealed that the anti-emetic effects of granisetron last only a relatively short time when the drug is administered once or even twice per day; however, the effects of palonosetron persist over its long plasma elimination half-life, which facilitates continuous supportive therapy of a daily regimen following nausea. Furthermore, comparing the relative costs in the treatment of bone and soft tissue tumors, Kimura et al (20) demonstrated that a single dose of palonosetron was in no way inferior to continuous administration of multiple doses of granisetron. In the current analysis, palonosetron is also more cost-effective and is not inferior to granisetron when used in continuous administration regimens.
These results suggest that palonosetron is a highly effective 5-HT3 receptor antagonist anti-emetic for use with the daily administration of an antineoplastic agent, in terms of medical efficacy and cost-effectiveness.
It must be noted that, due to the retrospective study design, the current results may be skewed by the fact that the attending physicians decided whether granisetron or palonosetron were administered alone or in combination with aprepitant. This is an issue that may be addressed in a future study.
Guidelines developed by the Japanese Society of Medical Oncology note that ‘When a clinician underestimates the occurrence of nausea, this indicates that vomiting is even less well controlled’ (21). Therefore, there is a requirement for further investigation of additional effective anti-emetic therapies in the future.
In conclusion, the results of the present study suggest that, in the treatment of hematopoietic malignancies, palonosetron is an effective regimen to be administered alongside more than 5 continuous days of anti-cancer agents. Furthermore, the combination of palonosetron and aprepitant was revealed to be the optimal regimen.